Subtypes of depressive symptoms and inflammatory biomarkers: An exploratory study on a sample of HIV-positive patients

Brain, Behavior, and Immunity

Volumn 56, Issue , 2016, Pages 105-113

  Norcini Pala, A ^a   Steca, P ^b   Bagrodia, R ^c   Helpman, L ^a   Colangeli, V ^d   Viale, P ^d   Wainberg, M L ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Depression; HIV; Il 6; Monocytes; Somatic symptoms

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; CHRONIC INFLAMMATION; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EXPLORATORY RESEARCH; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NONHUMAN; PATIENT ASSESSMENT; PHYSICAL DISEASE; PRIORITY JOURNAL; SYMPTOM; VIRUS LOAD; BLOOD; CLASSIFICATION; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; BIOMARKERS; DEPRESSION; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; VIRAL LOAD;

EID: 84958568733     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.02.013     Document Type: Article

References (63)

1. Antelman G., Kaaya S., Wei R., Mbwambo J., Msamanga G.I., Fawzi W.W., et al. Depressive symptoms increase risk of HIV disease progression and mortality among women in tanzania. J. Acq. Immun. Def. Synd. 2007, 44:470-477.
2. Asparouhov T., Muthén B. Auxiliary variables in mixture modeling: 3-step approaches using Mplus. Mplus Web Notes 2013, 15:1-24.
3. Barroso J., Harmon J.L., Madison J.L., Pence B.W. Intensity, chronicity, circumstances, and consequences of HIV-related fatigue: a longitudinal study. Clin. Nurs. Res. 2013, 1-15.
4. Bipath P., Levay P.F., Viljoen M. The kynurenine pathway activities in a sub-Saharan HIV/AIDS population. BMC Infect. Dis. 2015, 15:346.
5. Boasso A., Herbeuval J.P., Hardy A.W., Anderson S.A., Dolan M.J., Fuchs D., et al. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2, 3-dioxygenase in plasmacytoid dendritic cells. Blood 2007, 109:3351-3359.
6. Breen E., Rezai A., Nakajima K., Beall G., Mitsuyasu R., Hirano T., et al. Infection with HIV is associated with elevated IL-6 levels and production. J. Immunol. 1990, 144:480-484.
7. Breitbart W., Rosenfeld B., Kaim M., Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch. Intern. Med. 2001, 161:411-420.
8. Capuron L., Fornwalt F.B., Knight B.T., Harvey P.D., Ninan P.T., Miller A.H. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?. J. Affect. Disord. 2009, 119:181-185.
9. Chapman D.P., Perry G.S., Strine T.W. The vital link between chronic disease and depressive disorders. Prevent. Chronic Dis. 2005, 2:A14.
10. Collins L.M., Lanza S.T. Latent Class and Latent Transition Analysis: With Applications in the Social, Behavioral, and Health Sciences 2013, 718. John Wiley & Sons.
11. Crane H.M., Lober W., Webster E., Harrington R.D., Crane P.K., Davis T.E., et al. Routine collection of patient-reported outcomes in an HIV clinic setting: the first 100 patients. Curr. HIV Res. 2005, 5:109-118.
12. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
13. Dickerson S.S., Kemeny M.E., Aziz N., Kim K.H., Fahey J.L. Immunological effects of induced shame and guilt. Psychosom. Med. 2004, 66:124-131.
14. Elliott A.J., Russo J., Roy-Byrne P.P. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen. Hosp. Psychiatry 2002, 24:43-47.
15. Ferrando S., Evans S., Goggin K., Sewell M., Fishman B., et al. Fatigue in HIV illness: relationship to depression, physical limitations, and disability. Psychosom. Med. 1998, 60:759-764.
16. Fiala M., Looney D.J., Stins M., Way D.D., Zhang L., Gan X., et al. TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol. Med. 1997, 3:553-564.
17. Fu X., Zunich S.M., O'Connor J.C., Kavelaars A., Dantzer R., Kelley K.W. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J. Neuroinflamm. 2010, 7:43.
18. Fu X., Lawson M.A., Kelley K.W., Dantzer R. HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner. J. Neuroinflamm. 2011, 8-88.
19. Fujigaki H., Saito K., Fujigaki S., Takemura M., Sudo K., Ishiguro H., et al. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J. Biochem. 2006, 139:655-662.
20. Gonzalez J.S., Batchelder A.W., Psaros C., Safren S.A. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J. Acq. Immun. Def. Synd. 2011, 58:181-187.
21. Herbein G., Varin A. The macrophage in HIV-1 infection: from activation to deactivation. Retrovirology 2010, 7:1-15.
22. Hill L., Lee K.C. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. Ann. Pharmacother. 2013, 47:75-89.
23. Horberg M.A., Silverberg M.J., Hurley L.B., Towner W.J., Klein D.B., Bersoff-Matcha S., et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J. Acq. Immun. Def. Synd. 2008, 47:384-390.
24. Jung T., Wickrama K. An introduction to latent class growth analysis and growth mixture modeling. Soc. Personal. Psychol. Compass 2008, 2:302-317.
25. Kaharuza F.M., Bunnell R., Moss S., Purcell D.W., Bikaako-Kajura W., Wamai N., et al. Depression and CD4 cell count among persons with HIV infection in Uganda. AIDS Behav. 2006, 10:105-111.
26. Kalichman S.C., Rompa D., Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. J. Nerv. Ment. Dis. 2000, 188:662-670.
27. Kedzierska K., Crowe S.M. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr. Med. Chem. 2002, 9:1893-1903.
28. Kedzierska K., Crowe S.M., Turville S., Cunningham A.L. The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev. Med. Virol. 2003, 13:39-56.
29. Kemeny M.E. Psychobiological responses to social threat: evolution of a psychological model in psychoneuroimmunology. Brain Behav. Immun. 2009, 23:1-9.
30. Kennard B., Brown L., Hawkins L., Risi A., Radcliffe J., Emslie G., et al. Development and implementation of health and wellness CBT for individuals with depression and HIV. Cogn. Behav. Pract. 2014, 21:237-246.
31. Kroenke K., Spitzer R.L., Williams J.B. The PHQ-9: validity of a brief depression severity measure. J. Gen. Intern. Med. 2001, 16:606-613.
32. Kuller L.H., Tracy R., Belloso W., De Wit S., Drummond F., Lane H.C., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008, 5:e203.
33. Lanza S.T., Tan X., Bray B.C. Latent class analysis with distal outcomes: a flexible model-based approach. Struct. Equation Model.: Multidiscip. J. 2013, 20:1-26.
34. Lawrence S.T., Willig J.H., Crane H.M., Ye J., Aban I., Lober W., et al. Routine, self administered, touch-screen, computer-based suicidal ideation assessment linked to automated response team notification in an HIV primary care setting. Clin. Infect. Dis. 2010, 50:1165-1173.
35. Lawson M.A., Kelley K.W., Dantzer R. Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2, 3-dioxygenase expression: a possible mechanism for AIDS comorbid depression. Brain Behav. Immun. 2011, 25:1569-1575.
36. Lee K.A., Gay C., Portillo C.J., Coggins T., Davis H., Pullinger C.R., et al. Types of sleep problems in adults living with HIV/AIDS. J. Clin. Sleep Med. 2012, 8:67-75.
37. Lee K.A., Gay C.L., Lerdal A., Pullinger C.R., Aouizerat B.E. Cytokine polymorphisms are associated with fatigue in adults living with HIV/AIDS. Brain Behav. Immun. 2014, 40:95-103.
38. Lépine J.P., Briley M. The increasing burden of depression. Neuropsychiatr. Dis. Treat. 2011, 7:3-7.
39. Lima V.D., Geller J., Bangsberg D.R., Patterson T.L., Daniel M., Kerr T., Montaner J., et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007, 21:1175-1183.
40. Low Y., Preud'homme X., Goforth H.W., Omonuwa T., Krystal A.D. The association of fatigue with depression and insomnia in HIV-seropositive patients: a pilot study. Sleep 2011, 34:1723-1726.
41. Martinez P., Tsai A.C., Muzoora C., Kembabazi A., Weiser S.D., Huang Y., Haberer J., et al. Reversal of the kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans. JAIDS HR 2014, 65:456-462.
42. Moussavi S., Chatterji S., Verdes E., Tandon A., Patel V., Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007, 370:851-858.
43. Muthén L.K., Muthén B. Mplus User's Guide 1998-2015, Muthén & Muthén, Los Angeles, CA. 7th ed.
44. Navikas V., Link J., Persson C., Olsson T., Höjeberg B., Ljungdahl A., et al. Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. JAIDS HR 1995, 9:484-489.
45. Nylund K.L., Asparouhov T., Muthén B.O. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct. Equation Model.: Multidiscip. J. 2007, 14:535-569.
46. Pence B.W., O'Donnell J.K., Gaynes B.N. Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care. AIDS 2012, 26:656-658.
47. Poli G., Kinter A., Justement J.S., Kehrl J.H., Bressler P., Stanley S., et al. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:782-785.
48. Rabkin J.G. HIV and depression: 2008 review and update. Curr. HIV/AIDS Rep. 2008, 5:163-171.
49. Raison C.L., Lucile C., Andrew H.M. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
50. Ratner K.G., Halim M.L., Amodio D.M. Perceived stigmatization, ingroup pride, and immune and endocrine activity evidence from a community sample of Black and Latina Women. Soc. Psychol. Personal. Sci. 2013, 4:82-91.
51. Rizzo R., Piccinelli M., Mazzi M.A., Bellantuono C., Tansella M. The personal health questionnaire: a new screening instrument for detection of ICD-10 depressive disorders in primary care. Psychol. Med. 2000, 30:831-840.
52. Schumacher J.E., McCullumsmith C., Mugavero M., Ingle-Pang P.E., Raper J.L., Willig J.H., Zhiying Y., et al. Routine depression screening in an HIV clinic cohort identifies patients with complex psychiatric co-morbidities who show significant response to treatment. AIDS Behav. 2013, 17:2781-2791.
53. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., Kirchner H. Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr. Scand. 1996, 94:198-204.
54. Shacham E., Nurutdinova D., Satyanarayana V., Stamm K., Overton E.T. Routine screening for depression: identifying a challenge for successful HIV care. AIDS Patient Care 2009, 23:949-955.
55. Simon G.E. Treating depression in patients with chronic disease. West. J. Med. 2001, 175:292-293.
56. Sterne J.A., Hernán M.A., Ledergerber B., Tilling K., Weber R., Sendi P., et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005, 366:378-384.
57. Suarez E.C., Krishnan R.R., Lewis J.G. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom. Med. 2003, 65:362-368.
58. Thieblemont N., Weiss L., Sadeghi H.M., Estcourt C., Haeffner-Cavaillon N. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur. J. Immunol. 1995, 25:3418-3424.
59. Udina M., Moreno-Espana J., Capuron L., Navines R., Farre M., Vieta E., et al. Cytokine-induced depression: current status and novel targets for depression therapy. CNS Neurol. Disord. Drug Targets 2014, 13:1066-1074.
60. Valkanova V., Ebmeier K.P., Allan C.L. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J. Affect. Disord. 2013, 150:736-744.
61. Wainberg M.L., McKinnon K., Cournos F. Epidemiology of psychopathology in HIV. HIV and Psychiatry 2014, 1-60. John Wiley & Sons Ltd. 1st ed. J. Joska, D. Stein, I. Grant (Eds.).
62. Zunszain P.A., Anacker C., Cattaneo A., Carvalho L.A., Pariante C.M. Glucocorticoids, cytokines and brain abnormalities in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:722-729.
63. Zunszain P.A., Hepgul N., Pariante C.M. Inflammation and depression. Curr. Top. Behav. Neurosci. 2012, 14:135-151.